Skip to main content
Smart Investors Daily
LN

NASDAQ · LNDC

Landec Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

$8.76

Down-$0.32 (-3.52%)

Updated Sep 16, 2026, 2:14 AM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
263.63M
P/E ratio
-7.47
Dividend yield
0.00%
52-week range
— – —
Volume
52.47K
Avg. volume
64.27K

Price performance

LNDC price history

1M range · 0 trading sessions · Daily adjusted prices

LNDC does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest LNDC news

The latest Smart Investors Daily articles mentioning LNDC.

LNDC research

Overview

Company profile and research snapshot.

Company profile

Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$13.00
Implied upside
Analysts
LNDC recent ratings
DateFirmRatingTarget
Oct 7, 2022Barrington ResearchOutperform
Aug 11, 2022Barrington ResearchOutperform
Jul 20, 2022Stephens & Co.Overweight
Apr 6, 2022Barrington ResearchMarket Perform
Oct 4, 2021Roth CapitalBuy
Open full forecast

News briefing

No generated briefing is available yet.

Zacks Investment Research · Oct 6, 2022

Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates

Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewswire Inc. · Oct 6, 2022

Landec Corporation Reports First Quarter Fiscal Year 2023 Results

Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress

GlobeNewswire Inc. · Sep 28, 2022

Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET

SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.